Last reviewed · How we verify
NCT07457710
Remote Haptic Rehabilitation for Parkinson's Disease
NA trial testing Haptic device in Parkinson's Disease (PD) in 20 participants. Not yet recruiting.
30 June 2027
Quick facts
| Lead sponsor | Virginia Polytechnic Institute and State University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 25 March 2026 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
Drugs / interventions tested
- Haptic device
- Non-haptic device
Conditions studied
- Parkinson's Disease (PD) — all drugs for Parkinson's Disease (PD) →
Sponsor
Virginia Polytechnic Institute and State University
Who can join
18 and older, any sex, with Parkinson's Disease (PD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Individuals with Parkinson's Disease (PD) often have motor difficulties that can negatively impact daily activities and their quality of life. Research has shown that to slow the progression of these symptoms, patients should partake in effective physical rehabilitation. However, effective physical rehabilitation has many barriers, including timing, cost, and other personal or system-level challenges. The purpose of this study is to evaluate the haptic remote rehabilitation system for patients with PD using a randomized controlled trial (RCT) in a field environment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07457710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson's Disease (PD)
Currently open trials in the same condition.
- NCT07322887 — A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreate · Phase 2 · recruiting
- NCT07348705 — Electrophysiology-based DBS Programming for PD · NA · recruiting
- NCT07316296 — Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi · Phase 3 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07310264 — Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease · Phase 1 · recruiting
Other Virginia Polytechnic Institute and State University trials
Trials by the same sponsor.
- NCT07521072 — Testing an Intervention for College Students With Food Insecurity and Binge Eating · EARLY_PHASE1 · not yet recruiting
- NCT07042373 — Effects of Tobacco Abuse Liability-dependent Taxes in the ETM · NA · not yet recruiting
- NCT07158749 — Generalized and Domain-Specific Episodic Thinking for Smoking Cessation · NA · not yet recruiting
- NCT05103514 — The Longitudinal Impact of SES and the CNDS on Recovery From SUD · withdrawn
- NCT07161050 — Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07457710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Polytechnic Institute and State University
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07457710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing